company background image
BBIO logo

BridgeBio Pharma NasdaqGS:BBIO Stock Report

Last Price

US$28.53

Market Cap

US$5.4b

7D

2.6%

1Y

-32.1%

Updated

24 Dec, 2024

Data

Company Financials +

BridgeBio Pharma, Inc.

NasdaqGS:BBIO Stock Report

Market Cap: US$5.4b

BBIO Stock Overview

A commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. More details

BBIO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

BridgeBio Pharma, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for BridgeBio Pharma
Historical stock prices
Current Share PriceUS$28.53
52 Week HighUS$44.32
52 Week LowUS$21.62
Beta1.06
1 Month Change21.82%
3 Month Change16.40%
1 Year Change-32.06%
3 Year Change112.43%
5 Year Change-18.60%
Change since IPO3.56%

Recent News & Updates

BridgeBio: Next Chapter Begins After Attruby Approval

Nov 24

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analysts Are More Bearish Than They Used To Be

Nov 19
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analysts Are More Bearish Than They Used To Be

Recent updates

BridgeBio: Next Chapter Begins After Attruby Approval

Nov 24

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analysts Are More Bearish Than They Used To Be

Nov 19
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analysts Are More Bearish Than They Used To Be

Revenues Not Telling The Story For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Sep 24
Revenues Not Telling The Story For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis

Aug 31

BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon

Aug 17

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

Jun 10
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)

Jun 03

BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck

Jan 11

Shareholder Returns

BBIOUS BiotechsUS Market
7D2.6%-3.3%-2.2%
1Y-32.1%-1.9%23.9%

Return vs Industry: BBIO underperformed the US Biotechs industry which returned -1.9% over the past year.

Return vs Market: BBIO underperformed the US Market which returned 23.9% over the past year.

Price Volatility

Is BBIO's price volatile compared to industry and market?
BBIO volatility
BBIO Average Weekly Movement8.1%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: BBIO has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: BBIO's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015553Neil Kumarbridgebio.com

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

BridgeBio Pharma, Inc. Fundamentals Summary

How do BridgeBio Pharma's earnings and revenue compare to its market cap?
BBIO fundamental statistics
Market capUS$5.39b
Earnings (TTM)-US$438.86m
Revenue (TTM)US$217.77m

24.8x

P/S Ratio

-12.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BBIO income statement (TTM)
RevenueUS$217.77m
Cost of RevenueUS$2.39m
Gross ProfitUS$215.37m
Other ExpensesUS$654.23m
Earnings-US$438.86m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.32
Gross Margin98.90%
Net Profit Margin-201.53%
Debt/Equity Ratio-141.1%

How did BBIO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 21:51
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BridgeBio Pharma, Inc. is covered by 24 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
George FarmerBMO Capital Markets Equity Research
Konstantinos BiliourisBMO Capital Markets Equity Research
Jason ZemanskyBofA Global Research